Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels

This publication has 13 references indexed in Scilit:

• Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients
  The Lancet, 1994
• Pravastatin, lipids, and major coronary events
  The American Journal of Cardiology, 1994
• Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
  Circulation, 1994
• Moderate Alcohol Intake, Increased Levels of High-Density Lipoprotein and Its Subfractions, and Decreased Risk of Myocardial Infarction
  New England Journal of Medicine, 1993
• Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors
  The American Journal of Cardiology, 1993
• Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)
  The American Journal of Cardiology, 1991
• An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence.
  Circulation, 1990
• Reduction of Mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by Combined Treatment with Clofibrate and Nicotinic Acid
  Acta Medica Scandinavica, 1988
• Ischaemic Heart Disease: A Secondary Prevention Trial Using Clofibrate
  BMJ, 1971
• A Controlled Clinical Trial of a Diet High in Unsaturated Fat in Preventing Complications of Atherosclerosis
  Circulation, 1969